+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Detection of KRAS mutations in tumor cells using biochips

Detection of KRAS mutations in tumor cells using biochips

Molekuliarnaia Biologiia 45(5): 863-870

Somatic mutations in the KRAS gene are important markers of some types of tumors, for example, pancreatic cancer, and may be useful in early diagnostics. A biochip has been developed which allows determining most frequent mutations in 12, 13 and 61 codons of the KRAS gene. To increase the sensitivity of the method and to make possible the analysis of minor fractions of tumor cells in clinical samples the method of blocking a wild type sequence PCR amplification by LNA-oligonucleotides has been used. The product of LNA-clamp PCR was further hybridized with oligonucleotide probes, immobilized on biochip. Biochip was tested with 42 clinical DNA samples from patients with pancreatic cancer, mostly ductal adenocarcinomas. As reference methods, the RFLP analysis and sequencing were used. The developed approach allows detecting somatic mutations in the KRAS gene if the portion of tumor cells with mutation is at least 1% of whole cell population.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 052517188

Download citation: RISBibTeXText

PMID: 22393783

Related references

Detection of KRAS mutations in tumor cells using biochips. Molecular Biology 45(5): 797-803, 2011

In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells. Clinical Chemistry, 2018

Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer. Cancer Biology & Therapy 16(9): 1289-1295, 2016

Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma. Lung Cancer 100: 1-4, 2016

Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer. Translational Oncology 10(4): 693-698, 2017

Sensitive genotyping of somatic mutations in the EGFR, KRAS, PIK3CA, BRAF genes from NSCLC patients using hydrogel biochips. Applied Immunohistochemistry & Molecular Morphology 23(4): 255-265, 2015

Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer. Clinical Chemistry 62(11): 1482-1491, 2016

QIAGEN Therascreen KRAS RGQ Assay, QIAGEN KRAS Pyro Assay, and Dideoxy Sequencing for Clinical Laboratory Analysis of KRAS Mutations in Tumor Specimens. Laboratory Medicine 47(1): 30-38, 2016

Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis. Oncotargets and Therapy 10: 945-953, 2017

KRAS mutations in pancreatic circulating tumor cells: a pilot study. Tumour Biology 37(6): 7547-7554, 2015

Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment. Clinical Lung Cancer 18(6): 692-697, 2017

Label-Free Biochips for Accurate Detection of Prostate Cancer in the Clinic: Dual Biomarkers and Circulating Tumor Cells. Theranostics 7(17): 4289-4300, 2017

Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325(5947): 1555-1559, 2009

Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine, 2018

No duplicate KRAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple KRAS mutations. Journal of International Medical Research 35(4): 450-457, 2007